

Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation [Corrigendum]

Wang S, Wang T, Wang L, Zhong L, Li K. *Onco Targets Ther.* 2020;13:10917–10929.

The authors apologize for this error and advise it does not affect the results of the paper.

The authors have advised due to an error at the time of figure assembly, [Figure 6A](#) on page 10926 is incorrect.

The correct [Figure 6](#) is shown below.




Figure 6 RNF126 promoted cell mobility in vitro in p53 dependent-ubiquitination. Cell invasion (**A**) and migration (**B**) in siCtrl, si1-RNF126 and si1-RNF126 plus si-p53 groups in HCT116 cells. Cell invasion (**C**) and migration (**D**) in GFP, RNF126-GFP, and RNF126-GFP+MG132 groups of HCT-8 cells. (A) siCtrl group; (B) si1-RNF126 group; (C) si1-RNF126 group plus si-p53 group; (D) GFP group; (E) RNF126-GFP group; (F) RNF126-GFP group plus MG132 group. Bars indicate \pm SE. * $P < 0.05$; ** $P < 0.01$ compared with the control.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.534838>